J. Pursley

发表

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.

A. Shenker, C. Frost, Jessie Wang, 2014, British journal of clinical pharmacology.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

C. Frost, Jessie Wang, Y. Barrett, 2012, Thrombosis and Haemostasis.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

C. Frost, Jessie Wang, Y. Barrett, 2013, British journal of clinical pharmacology.

Liquid-liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry.

Y. Xue, J. Pursley, M. Arnold, 2007, Journal of pharmaceutical and biomedical analysis.

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

A. Shenker, C. Frost, Jessie Wang, 2018, Clinical pharmacology : advances and applications.

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

C. Frost, Jessie Wang, R. Boyd, 2016, Journal of clinical pharmacology.

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

C. Frost, Jessie Wang, F. LaCreta, 2013, Clinical pharmacology : advances and applications.

LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column.

Jim X. Shen, A. Schuster, Oanh T Dang, 2014, Bioanalysis.

Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.

Hao Jiang, T. Eley, B. He, 2015, Journal of pharmaceutical and biomedical analysis.

Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans

V. Arora, A. Allentoff, J. Gan, 2011, Drug Metabolism and Disposition.

Metabolism and Disposition of [ 14 C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans □ S

V. Arora, A. Allentoff, J. Gan, 2011 .

Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L 6 by Deoxyspergualin 1

G. Hortobagyi, V. Valero, D. Booser, 2006 .

Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L6 by Deoxyspergualin1

Herbert, D. Booser, A. Buzdar, 2006 .

Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study.

S. Unger, J. Pursley, M. Arnold, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology

Yuan-qing Xia, M. Jemal, J. Gan, 2012, Drug Metabolism and Disposition.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.

C. Frost, Jessie Wang, F. LaCreta, 2014, International journal of clinical pharmacology and therapeutics.

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

C. Frost, Jessie Wang, Y. Barrett, 2014, Clinical pharmacology : advances and applications.

A simple 96-well liquid-liquid extraction with a mixture of acetonitrile and methyl t-butyl ether for the determination of a drug in human plasma by high-performance liquid chromatography with tandem mass spectrometry.

J. Pursley, M. Arnold, Y. Xue, 2004, Journal of pharmaceutical and biomedical analysis.

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

Response to Letter to the Editor From Drs. Stöllberger and Finsterer

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

apixaban Pharmacokinetics and Pharmacodynamics in Subjects With Renal Impairment : 1381212

A. Shenker, C. Frost, Jessie Wang, 2012 .

Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

C. Frost, Jessie Wang, F. LaCreta, 2014 .

Disposition of radiolabeled BMS‐204352 in rats and dogs

R. Krishna, N. Srinivas, M. Yao, 2002, Biopharmaceutics & drug disposition.

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

Dianna Y. Wu, Jinshan Shen, E. Masson, 2013, Clinical Drug Investigation.

lack of Pharmacokinetic Interaction Between Apixaban and Prasugrel in Healthy Subjects : 2-55-2000112

C. Frost, F. LaCreta, J. Pursley, 2014 .

Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors

T. Mekhail, R. Ganapathi, J. Gan, 2010, Drug Metabolism and Disposition.

A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma.

S. Unger, Jane Liu, Steve Unger, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.

G. Hortobagyi, V. Valero, D. Booser, 1995, Cancer research.

Studies on the pharmacokinetics and metabolism of a γ-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction

J. Lubinski, O. Flint, D. Boulton, 2009, Xenobiotica; the fate of foreign compounds in biological systems.